Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27162932 | 0.90 | GPR119 (0.43) | GPR119HRH3HPGDUSP2SMN1; SMN2 | |
| SCHEMBL346826 | 0.87 | HPGD (0.47) | GPR119HRH3HPGDUSP2SMN1; SMN2 | |
| SCHEMBL2870337 | 0.87 | L3MBTL3 (0.44) | GPR119HRH3CYP1A2L3MBTL3L3MBTL1 | |
| SCHEMBL118654 | 0.84 | CYP1A2 (0.50) | GPR119CYP1A2USP2SMN1; SMN2 | |
| SCHEMBL346049 | 0.84 | GPR119 (0.36) | GPR119HRH3CYP1A2L3MBTL3L3MBTL1 | |
| Hydrochloric Acid SCHEMBL2075849 | 0.83 | CYP1A2 (0.49) | GPR119CYP1A2USP2SMN1; SMN2 | |
| SCHEMBL29976531 | 0.82 | ITGB3 (0.42) | HRH3CYP1A2L3MBTL3L3MBTL1 | |
| SCHEMBL22565580 | 0.81 | ACACB (0.42) | HRH3L3MBTL3L3MBTL1HPGDUSP2 | |
| SCHEMBL30135841 | 0.81 | HPGD (0.45) | GPR119HRH3HPGDUSP2SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL15571773 | 0.81 | CYP1A2 (0.44) | GPR119CYP1A2USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073662-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI (FR) | 2014-03-13 | — | — | US | disclosed |
| US-8609681-B2 | Spirocyclic nitriles as protease inhibitors | SANOFI (FR) | 2013-12-17 | — | — | US | disclosed |
| US-20120015933-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015933-A1 | Spirocyclic nitriles as protease inhibitors | CTRL, SERPINB1, PREP | GPR119 4318/4885HRH3 4003/4885CYP1A2 638/4885 |
| US-20140073662-A1 | Spirocyclic nitriles as protease inhibitors | CTRL, SERPINB1, PREP | GPR119 4318/4885HRH3 4003/4885CYP1A2 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.